Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate

Biologicals

Volumn 38, Issue 6, 2010, Pages 658-663

  Yu, Yun Zhou ^a   Wang, Wen Bin ^a   Li, Na ^a   Wang, Shuang ^a   Yu, Wei Yuan ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Aluminum phosphate; Bivalent vaccine; Botulinum neurotoxin; DNA vaccine; Replicon

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BOTULINUM NEUROTOXIN SEROTYPE A HC DOMAIN PLASMID DNA REPLICON VACCINE; BOTULINUM NEUROTOXIN SEROTYPE A HC DOMAIN PLASMID DNA VACCINE; BOTULINUM NEUROTOXIN SEROTYPE B HC DOMAIN PLASMID DNA REPLICON VACCINE; BOTULINUM NEUROTOXIN SEROTYPE B HC DOMAIN PLASMID DNA VACCINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PLASMID DNA; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BOTULISM; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; SURVIVAL RATE; TH2 CELL; VACCINATION;

ADSORPTION; ALUMINUM COMPOUNDS; ANIMALS; ANTIBODIES; CHEMISTRY, PHARMACEUTICAL; DNA REPLICATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICE; NEUTRALIZATION TESTS; PHOSPHATES; PLASMIDS; REPLICON; VACCINES, DNA;

MUS;

EID: 78650234499     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2010.08.001     Document Type: Article

References (37)

1. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rew 2000, 80:717-766.
2. Turton K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002, 27(11):552-558.
3. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966.
4. Middlebrook J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev 2005, 57:1415-1423.
5. Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 2007, 27:303-318.
6. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998, 66:4817-4822.
7. Holley J.L., Elmore M., Mauchline M., Minton N., Titball R.W. Cloning, expression and evaluation sub-unit vaccine against Clostridium type F toxin. Vaccine 2001, 19:288-297.
8. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 2004, 572:299-306.
9. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007, 75:3043-3054.
10. Baldwin M.R., Tepp W.H., Przedpelski1 A., Pier C.L., Bradshaw M., Johnson E.A., et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008, 76:1314-1318.
11. Yu Y.Z., Li N., Wang R.L., Zhu H.Q., Wang S., Yu W.Y., et al. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol 2008, 15:1819-1823.
12. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27:2816-2822.
13. Clayton Jennifer, John L. Middlebrook. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000, 18:1855-1862.
14. Shyu R.H., Shaio M.F., Tang S.S., Shyu H.F., Lee C.F., Tsai M.H., et al. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed Sci 2000, 7:51-57.
15. Bennett A.M., Perkins S.D., Holley J.L. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 2003, 21:3110-3117.
16. Jathoul A.P., Holley J.L., Garmory H.S. Efficacy DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 2004, 22:3942-3946.
17. Yu Y.Z., Zhang S.M., Sun Z.W., Wang S., Yu W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 2007, 25:8843-8850.
18. Yu Y.Z., Yu Jiyu, Li N., Wang R.L., Wang S., Yu W.Y., et al. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors. Vaccine 2009, 27:6148-6153.
19. Lee J.S., Pushko P., Parker M.D., Dertzbaugh M.T., Smith L.A., Smith J.F. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 2001, 69:5709-5715.
20. Lee J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S.L., et al. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006, 24:6886-6892.
21. Ulmer J.B., Wahren B., Liu M.A. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006, 12:216-222.
22. Dhama K., Mahendran M., Gupta P.K., Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet Res Commun 2008, 32:341-356.
23. Tjelle T.E., Salte R., Mathiesen I., Kjeken R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 2006, 24:4667-4670.
24. Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2003, 2:305-315.
25. Lu S., Wang S., Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008, 7:175-191.
26. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82:488-496.
27. Lindblad E.B. Aluminum adjuvants-in retrospect and prospect. Vaccine 2004, 22:3658-3668.
28. Lindblad E.B. Aluminum compounds for use in vaccines. Immunol Cell Biol 2004, 82:497-505.
29. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donnelly J.J., McClements W.L., et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 1999, 18:18-28.
30. Wang S., Liu X., Fisher K., Smith J.Z., Chen F., Tobery T.W., et al. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum-phosphate. Vaccine 2000, 18:1227-1235.
31. Kwissa M., Lindblad E.B., Schirmbeck R., Reimann J. Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response. J Mol Med 2003, 81:502-510.
32. Fischer L., Minke J., Dufay N., Baudu P., Audonnet J.C. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine 2003, 21:4593-4596.
33. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77:6305-6313.
34. Temperton N.J., Quenelle D.C., Lawson K.M., Zuckerman J.N., Kern E.R., Griffiths P.D., et al. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. J Med Virol 2003, 70:86-90.
35. Rosado-Vallado M., Mut-Martin M., García-Miss Mdel R., Dumonteil E. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana. Vaccine 2005, 23:5372-5379.
36. Jones R.G.A., Corbel M.J., Sesardic D. A review of WHO International Standards for botulinum antitoxins. Biologicals 2006, 34:223-226.
37. Yu Y.Z., Li N., Wang S., Yu W.Y., Sun Z.W. Improved immunogenicity and protective efficacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting. Immunopharmacol Immunotoxicol 2009, 31:397-404.